Sartorius stock holds steady as full-year 2025 figures frame valuation
Published on 09/14/2026 at 19:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sartorius stock (ISIN DE0006292006) is trading in a relatively stable range in mid-September 2026 as investors continue to price in the company’s audited full-year 2025 results, which were published on February 16, 2026 and now form the latest comprehensive basis for valuation.
Full-year 2025 figures underpin Sartorius valuation
According to an update on Bio-Rad Laboratories’ investment in Sartorius that reproduces data from Sartorius’ audited consolidated financial statements for fiscal year 2025, the company generated sales revenue of EUR 3,538.1 million for the year ended December 31, 2025, marking a substantial scale for its bioprocess and laboratory solutions business.StockTitan In the same period, Sartorius reported gross profit of EUR 1,636.7 million, which translates into a gross margin of about 46.2 percent for fiscal year 2025 when measured against total sales revenue of EUR 3,538.1 million.StockTitan
Earnings before interest and taxes (EBIT) for the year ended December 31, 2025 amounted to EUR 542.6 million, implying an EBIT margin of around 15.3 percent on the EUR 3,538.1 million revenue base and highlighting the profitability the group was able to sustain at the end of 2025.StockTitan Net profit came in at EUR 230.4 million for fiscal year 2025, which corresponds to a net margin of approximately 6.5 percent when set against total sales revenue and gives investors a sense of the earnings conversion from Sartorius’ top line into bottom line results.StockTitan
Cash flow from operating activities reached EUR 837.0 million in fiscal year 2025, underlining Sartorius’ ability to translate its earnings and working-capital management into strong cash generation.StockTitan By contrast, cash flows from investing and financing activities were negative at EUR 513.7 million and EUR 591.4 million, respectively, reflecting a combination of capital expenditure, investment activity and financing decisions such as debt servicing or dividend payments over the year.StockTitan
On the balance sheet side, as of December 31, 2025 Sartorius reported current assets of EUR 1,766.2 million and non-current assets of EUR 7,951.1 million, underpinning the sizeable asset base required to support its global manufacturing network and installed equipment at customer sites.StockTitan Current liabilities stood at EUR 1,967.4 million, while non-current liabilities amounted to EUR 3,882.6 million, and equity totaled EUR 3,867.2 million at the end of fiscal year 2025, illustrating a capital structure in which equity and longer-term liabilities together finance the bulk of Sartorius’ asset base.StockTitan
Investor focus on margins and cash generation
For investors assessing Sartorius stock in September 2026, the fiscal year 2025 figures provide a reference point for profitability and cash generation ahead of newer interim results, even though they represent a historical snapshot rather than the current year’s performance. The EBIT margin of about 15.3 percent for fiscal year 2025 shows that Sartorius was able to maintain double-digit operating profitability in its bioprocess solutions and laboratory products activities, a level that often serves as a benchmark when comparing Sartorius to other life-sciences and bioprocess equipment providers in Europe and globally.StockTitan
The historical net profit margin of approximately 6.5 percent for fiscal year 2025 indicates that while Sartorius’ business model is capital-intensive and entails meaningful depreciation, interest and tax charges, the group nonetheless delivered positive earnings, supporting its ability to reinvest in capacity and innovation.StockTitan Investors considering Sartorius stock often weigh how this profitability profile compares with both historical levels and peers, as well as how margin dynamics might evolve as biopharma capital spending cycles fluctuate.
The operating cash flow of EUR 837.0 million in fiscal year 2025 is another key historical figure for the market, since strong cash generation can help buffer periods of softer revenue growth or margin pressure.StockTitan At the same time, the negative cash flows from investing and financing activities show that Sartorius has been actively deploying capital, whether in the form of expansion projects, acquisitions or balance-sheet optimization, which investors need to factor into their assessment of leverage and future returns.
Beyond the group’s financial profile, Sartorius is also positioned as a leading player in specialized laboratory services such as pipette calibration and performance verification, which form part of broader service offerings to pharmaceutical, biotechnology and research laboratories.MarketsandMarkets This positioning supports the company’s long-term growth case by tying Sartorius not only to equipment sales but also to recurring service revenue driven by quality and regulatory requirements in regulated laboratory environments.
Sartorius stock and sector sentiment
Sector sentiment around life-sciences and bioprocessing names also plays into how Sartorius stock is valued in late 2026. In the broader biotechnology and bioprocessing space, Sartorius Stedim Biotech, which is related to Sartorius, is cited with an average analyst price target of EUR 240 against a current level of EUR 184.30, indicating upside potential of around 30 percent according to a German-language sector overview.FinanzNachrichten While this figure refers specifically to Sartorius Stedim Biotech rather than Sartorius AG, it nonetheless illustrates that analysts still see room for appreciation in parts of the broader Sartorius group’s equity footprint when measured against current prices in September 2026.
For holders of Sartorius stock, the key question is how the group’s margins and cash flows from fiscal year 2025 will translate into the current and upcoming reporting periods, and whether sector demand for bioprocess and laboratory solutions remains robust enough to support further revenue growth and profit expansion. Historical figures such as the EUR 3,538.1 million revenue and EUR 542.6 million EBIT for fiscal year 2025, coupled with the strong operating cash flow, set a baseline that investors can use to gauge any acceleration or moderation when newer quarterly or half-year results become available.StockTitan
Stock price context and investor takeaway
In the absence of a major new catalyst right around September 14, 2026, Sartorius stock’s day-to-day movements are largely driven by broader sector sentiment, interest-rate expectations and investors’ views on how quickly the group can build on its fiscal year 2025 profitability and cash generation. For medium-term investors, the combination of a double-digit EBIT margin, positive net earnings, solid operating cash flow and a sizeable equity base of EUR 3,867.2 million at the end of 2025 provides a framework for assessing the risk-reward profile of Sartorius stock in the context of the European life-sciences equipment sector.StockTitan
Key data on Sartorius stock
- Company: Sartorius AG
- ISIN: DE0006292006
- WKN: 629200
- Ticker: SRT3
- Trading venue: Xetra
- Sector / Industry: Life sciences tools and services / biotechnology equipment
- Index membership: MDAX
